Vitamin D for Rickets

Vitamin D, together with calcium, is the standard treatment and the standard prevention for nutritional rickets, the soft-bone disease of growing children. A global consensus of 33 experts recommends 400 IU a day for every infant to prevent it and at least 2,000 IU a day for at least 3 months, plus calcium, to treat it (Munns 2016). In prevention trials, no supplemented infant developed rickets at 400 IU a day, while 3.8% of unsupplemented Turkish infants did (Munns 2016).

The honest caveats: treatment trials mostly compared doses and calcium regimens rather than vitamin D against placebo, and the Cochrane review grades the pooled evidence low certainty (Chibuzor 2020). Where children eat very little calcium, calcium mattered as much as vitamin D, and in one large trial a 100,000 IU dose every 3 months did not prevent rickets (Crowe 2021). That is why the verdict is likely/moderate, not strong.

The two forms appear to cure rickets about equally well, but D3 raises blood levels more in most trials. Our vitamin D2 vs D3 guide covers the evidence.

Vitamin D promotes calcium absorption in the gut and keeps blood calcium and phosphate high enough for normal bone mineralisation, and it is needed for bone growth and remodelling (NIH Office of Dietary Supplements). Rickets is what happens when growing bone cannot mineralise: bones soften and deform, and severe cases bring failure to thrive, seizures from low blood calcium and heart muscle disease.

Blood levels give the working picture. The NIH describes a 25-hydroxyvitamin D below 30 nmol/L as linked to rickets and 50 nmol/L or more as adequate for most people. In a meta-analysis of 5,412 young children, 62% of those with rickets had levels below 30 nmol/L (Rios-Leyvraz 2024).

Low vitamin D does not explain every case. Among Nigerian children with rickets, only 37% had 25-hydroxyvitamin D below 30 nmol/L, and the authors concluded vitamin D deficiency was unlikely to be the primary cause there (Thacher 2000). In India, children with rickets ate far less calcium than controls (204 versus 453 mg a day), while their vitamin D levels did not differ significantly from controls (Aggarwal 2012).

The same meta-analysis found the risk threshold depends on calcium: about 28 nmol/L when calcium intake is adequate and about 40 nmol/L when it is low (Rios-Leyvraz 2024). So the same vitamin D level can be safe in one child and rachitic in another, depending on diet. A systematic review describes a spectrum from isolated vitamin D deficiency to isolated calcium deficiency (Creo 2017).

For prevention, the consensus recommends 400 IU (10 mcg) a day from birth to 12 months, independent of feeding, and at least 600 IU (15 mcg) a day after 12 months (Munns 2016). The NIH Adequate Intake for infants is the same 400 IU, and its recommended intake is 600 IU a day for ages 1 to 18.

For treatment, the consensus sets a minimum of 2,000 IU a day for at least 3 months with at least 500 mg a day of calcium, rising with age (table below). It prefers oral over intramuscular dosing, treats D2 and D3 as equal when given daily, and prefers D3 for single large doses. Check labels carefully: 1 mcg of vitamin D equals 40 IU.

The consensus reports that 400 IU a day prevents radiographic rickets: no confirmed rickets was reported anywhere in infants or children taking 400 IU regularly, against a 3.8% incidence in unsupplemented Turkish infants (Munns 2016). In the Cochrane review of prevention trials, vitamin D versus no treatment in Turkish children up to 3 years had a relative risk of rickets of 0.04 (95% CI 0 to 0.71), though only four studies of about 1,700 children existed (Lerch 2007).

Dose trials agree. In 256 Chinese infants, none had rickets at 6 months on 100, 200 or 400 IU a day, and 25-hydroxyvitamin D rose with the dose (Specker 1992). A meta-analysis of 61 infant studies found 400 IU a day was sufficient to reach 25-hydroxyvitamin D concentrations able to prevent rickets, with 250 nmol/L not exceeded in at least 97.5% of infants up to 1,200 IU a day (Zittermann 2020).

The treatment trials we found compared vitamin D with calcium or with other regimens, not with placebo alone, and the Cochrane review found only four small trials of 286 children comparing vitamin D with calcium (Chibuzor 2020). In Nigeria, 123 children with rickets eating about 200 mg of calcium a day were given vitamin D (600,000 IU intramuscularly at enrolment and again at 12 weeks), calcium (1,000 mg a day) or both for 24 weeks: the healing endpoint was reached by 19%, 61% and 58% (P less than 0.001) (Thacher 1999). Adding monthly vitamin D2 to limestone calcium, against placebo, showed only a trend (67% versus 44%, P = 0.06) (Thacher 2014).

In India and Istanbul the combination did best. In 67 Indian children, most with low vitamin D, the combination healed 50% by 12 weeks, against 15.7% on vitamin D alone and 11.7% on calcium alone (Aggarwal 2013). In 42 Istanbul infants, serum calcium rose most with vitamin D plus calcium, and the authors judged vitamin D deficiency the primary cause there (Kutluk 2002). Overall, Cochrane graded vitamin D plus calcium better than vitamin D alone (RR 3.06, 95% CI 1.49 to 6.29, low certainty) and could not tell it from calcium alone (RR 1.17, 95% CI 0.72 to 1.90, very low certainty) (Chibuzor 2020).

A 2026 meta-analysis of four trials found no significant or clinically meaningful difference between low-dose (up to 300,000 IU) and high-dose (300,000 to 600,000 IU) regimens, with no serious adverse events (Kaur 2026). Single oral doses of 90,000 and 300,000 IU both healed rickets (X-ray score fell from about 6.9 to under 0.3), but hypercalcaemia and hypercalciuria were more common at 300,000 IU (Mittal 2018). A single oral depot dose matched 12 weeks of daily drops (93.9% healed in each group) (Saluja 2022), and 600,000 IU intramuscularly matched 60,000 IU weekly by mouth (Mondal 2014).

Daily dosing did at least as well: 2,000 IU a day healed 75% completely at 12 weeks against about 61% on weekly regimens (P = 0.15) (Dabas 2023), and 2,000, 3,000 and 4,000 IU a day were comparable, with high 25-hydroxyvitamin D and hypercalciuria only in the higher groups (Dabas 2026). The consensus nonetheless recommends daily oral treatment first (Munns 2016).

In Bangladesh, 1,300 pregnant women were randomised to placebo or weekly vitamin D. Biochemical rickets in infants was 7.8% on placebo and 1.3% when the mother took 28,000 IU a week from pregnancy to 6 months postpartum (RR 0.16, 95% CI 0.03 to 0.72); prenatal-only dosing did not differ significantly from placebo (Lautatzis 2024).

Cochrane found low-certainty evidence that maternal supplementation in high-risk groups reduced biochemical rickets (RR 0.06, 95% CI 0.01 to 0.44, two studies, 229 participants), but insufficient evidence for radiological rickets and for infants given 400 IU (Tan 2020).

Four gaps limit certainty. First, the trials we found did not test vitamin D alone against placebo for treatment, so guideline strength rests partly on physiology and indirect trials. Second, the dose-comparison trials are small, mostly open-label and mostly from India and Nigeria. Third, supplementation did not always work: 100,000 IU every 3 months left rickets at 5.3% versus 5.5% on placebo in Kabul (Crowe 2021), and vitamin D with or without calcium did not change rickets in Tibetan children (Rooze 2016). Fourth, the consensus covers nutritional rickets only; children with inherited rickets need a specialist.

At infant prevention doses vitamin D is well tolerated: 400 IU a day is the NIH Adequate Intake and sits below the upper limit of 1,000 IU a day to 6 months and 1,500 IU at 7 to 12 months. Treatment is where risk appears. Vitamin D toxicity causes hypercalcaemia (high blood calcium) and hypercalciuria (high urine calcium), almost always from supplement overuse, and in extreme cases kidney failure (NIH Office of Dietary Supplements). In treatment trials, hypercalcaemia was documented in 2 of 76 children at 4 weeks and 3 at 12 weeks after 300,000 or 600,000 IU (Mittal 2014) and in eight infants given 300,000 or 600,000 IU, six of them at 600,000 IU (Cesur 2003). Three young children developed hypercalcaemia on doses within accepted guidelines, which took 6 weeks to 6 months to resolve (Vanstone 2012).

A meta-analysis of 8 of 32 high-dose trials in children aged 0 to 6 (4,612 children) found no increase in serious adverse events (RR 1.01), and hypercalcaemia was not significantly increased (RR 1.18, 95% CI 0.72 to 1.93, n = 726), though the review was not limited to children with rickets (Brustad 2022). Pediatric Endocrine Society reviewers say true toxicity is rare and usually follows manufacturing, formulation or prescribing errors involving 240,000 to 4,500,000 IU, and suggest checking 25-hydroxyvitamin D in children on long-term doses at or above the upper limit (Vogiatzi 2014).

The NIH Office of Dietary Supplements lists four medicine classes that interact with vitamin D. Few apply to infants, but older children and teenagers on these medicines should have their vitamin D plan reviewed.